Vir Biotechnology has enrolled the first subject in the Phase III ECLIPSE registrational programme of tobevibart and ...

The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta (CHD). ECLIPSE 1 ...

“As we enter 2025, we are poised for significant advancement with the initiation of our phase 3 registrational program in chronic hepatitis delta and further clinical progression of our dual ...

Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA ...

There are five kinds of hepatitis. Each has different causes, with one commonality: Hepatitis causes your liver to get inflamed. Hepatitis disease can also sometimes be spread through sexual contact.

Mrs Tinubu referenced data from the Federal Ministry of Health and Social Welfare, which revealed that in 2024, over 100,000 children and nearly two million adults were living with HIV.

SAN FRANCISCO, CA, USA I March 13, 2025 I Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.